SRx Health Solutions (SRXH) Q3 2024 earnings summary

Executive summary

• Achieved 33% sequential sales growth to $11.4 million in Q3 2024, with net income of $1.5 million, marking the first profitable quarter in years and a 194% year-over-year increase.

• Gross margin improved to 40% for the third consecutive quarter, up from 34% in Q3 2023, driven by better pricing and product mix.

• Strategic exits from unprofitable channels, including DTC and certain brick & mortar, improved operating leverage and profitability.

• Strong digital and international channel performance, especially in Asia-Pacific, with double-digit growth in new and repeat consumers.

• Announced pending acquisition of SRx Health Solutions, a leading Canadian specialty pharmacy network, expected to close in early Q1 2025.

Financial highlights

• Q3 2024 net sales: $11.4 million, up 33% sequentially but down 13% year-over-year; nine months: $28 million, down from $33 million year-over-year.

• Gross profit for Q3 2024: $4.5 million, with gross margin at 40%, up 600 basis points year-over-year.

• Adjusted EBITDA margin reached 2% for the quarter, with adjusted EBITDA over $200,000, up 255% year-over-year.

• Net income for Q3 2024: $1.5 million (EPS $0.73–$0.74); nine months: $1.3–$1.4 million (EPS $1.07–$1.08).

• Net working capital increased to $9.5 million from $3.1 million last quarter; cash and cash equivalents at $4.7 million.

Outlook and guidance

• Management confident in continued top-line growth domestically and internationally, focusing on operational efficiencies and profitability.

• Expecting to maintain upward trajectory into 2025, leveraging improved working capital and margin expansion.

• Ongoing initiatives include margin improvement, innovation, and channel optimization.